A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Disease: Real-Life Data from the Sicilian Network for Inflammatory Bowel Disease

Antonio Carroccio, Salvatore Accomando, Mario Cottone, Mario Cottone, Michele Citrano, Sebastiano Siringo, Nunzio Belluardo, Filippo Mocciaro, Sara Renna, Rosalba Orlando, Giulia Rizzuto, Antonio Carroccio, Fabio Salvatore Macaluso, Salvatore Accomando, Antonio Carroccio, Claudio Romano, Marco Ventimiglia, Concetta Ferracane, Giovanni Magrì, Roberto VassalloCarmelo Bertolami, Antonino Trovatello, Serena Porcari, Salvatore Genova, Antonio Carroccio, Nunzio Belluardo, Sebastiano Siringo, Antonio Magnano, Gaetano Inserra, Roberto Di Mitri, Antonio Carlo Privitera, Antonio Magnano, Ambrogio Orlando, Walter Fries, Maria Cappello, Giuseppe Scarpulla

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Background and Aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn's disease [CD]. Methods Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-naïve and non-naïve patients. Results A total of 632 patients [735 total treatments] were included. Among naïve patients, a clinical benefit [the sum of steroid-free remission plus clinical response] was achieved in 81.8% patients treated with ADA and in 77.6% patients treated with IFX (adjusted odds ratio [OR]: 1.23, 95% CI 0.63-2-44, p = 0.547] at 12 weeks; after 1 year, a clinical benefit was achieved in 69.2% of patients treated with ADA and in 64.5% patients treated with IFX [adjusted OR: 1.10, 95% CI 0.61-1.96, p = 0.766]. Among non-naïve patients, a clinical benefit was achieved in 61.7% of patients treated with ADA and in 68.1% of patients treated with IFX [adjusted OR: 0.72, 95% CI 0.21-2.44, p = 0.600] at 12 weeks; after 1 year, a clinical benefit was achieved in 48.9% of patients treated with ADA and in 40.4% patients treated with IFX [adjusted OR: 1.23, 95% CI 0.54-2.86, p = 0.620]. Conclusions In this propensity score-matched comparison of ADA and IFX in CD, both drugs showed high rates of clinical benefit, without significant differences between them.
Original languageEnglish
Pages (from-to)209-217
Number of pages9
JournalJournal of Crohn's and Colitis
Volume13
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Fingerprint Dive into the research topics of 'A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Disease: Real-Life Data from the Sicilian Network for Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this